Abstract-Many biomedical problems relate to mutant functional properties across a sequence space of interest, e.g., flu, cancer, and HIV. Detailed knowledge of mutant properties and function improves medical treatment and prevention. A functional census of p53 cancer rescue mutants would aid the search for cancer treatments from p53 mutant rescue. We devised a general methodology for conducting a functional census of a mutation sequence space by choosing informative mutants early. The methodology was tested in a double-blind predictive test on the functional rescue property of 71 novel putative p53 cancer rescue mutants iteratively predicted in sets of three (24 iterations). The first double-blind 15-point moving accuracy was 47 percent and the last was 86 percent; r = 0.01 before an epiphanic 16th iteration and r = 0.92 afterward. Useful mutants were chosen early (overall r = 0.80).
INTRODUCTION
M UTATIONS and their functional effects drive evolution, drug resistance, genetic disorders, viral evasion of the immune system, and other important biomedical processes. In pharmacogenomics [1] and drug resistant HIV [2] , [3] , [4] , detailed knowledge of functionally important mutations leads directly to better patient treatment. In flu [5] , knowledge of important mutations leads directly to better disease prevention, by way of better vaccine design. In cancer, the concern of this paper, the effect of functionally important mutations causes the disease.
Medical practice is often advanced by knowing mutant functional properties across a mutation sequence space of specific interest. One difficulty is that mutation spaces grow to be combinatorially large, while experimental time and resources remain bounded. Computational analysis is challenging because subtle effects on structure and function result in broad and diverse changes.
p53 Overview
Cancer is caused by the accumulation of genetic mutations in two critical regulatory pathways: normal cell growth and programmed cell death (apoptosis). Defects in the cell growth pathway can result in uncontrolled cellular proliferation. Tumor suppressor proteins such as p53 normally trigger apoptosis in affected cells and destroy the tumor.
p53 exerts its tumor suppressor activity mainly as a transcription factor that induces cell cycle arrest, apoptosis, DNA repair, and/or senescence. It is stabilized and activated in response to cell stress by a complicated series of posttranslational modifications [6] , [7] , [8] , [9] . Activated p53 suppresses tumors through one of the following mechanisms:
1. Induction-p53 directly targets and induces genes with tumor suppressor functions [10] , [11] . There are approximately 100 known genes with p53 binding sites [12] and several hundred genes are directly or indirectly upregulated by activated p53 [13] , [14] . 2. Repression-p53 also represses the expression of genes. As most of the repressed genes lack a distinct p53 binding site, the mechanism is currently unknown [15] . 3. Nontranscriptional Mechanisms-p53 translocates to the mitochondria in response to DNA damage and causes cytochrome c release [16] , [17] . p53 mutations that disrupt these mechanisms are complicit in human cancers. The International Agency for Research on Cancer (IARC) TP53 Mutation Database 1 (R10) lists 21,588 p53 mutations found in human cancer patients [18] . Seventy-one percent of the entries (15, 387) result in full-length protein with a single amino acid change in the DNA binding p53 core domain. The top eight mutants account for 30 percent and the top 50 account for 54 percent of these single amino acid change mutants [19] . The structure of full-length wild-type p53 is unknown, but the crystal structure of the core domain [20] , in conjunction with biophysical and NMR studies [21] , [22] , [23] , has made it possible to construct homology models. p53 has 393 amino acids and three important domains: an amino-terminal transactivation domain, a core domain consisting of amino acids 96-292 which recognizes p53 DNA binding sites, and a carboxy-terminal tetramerization domain [24] , [25] , [26] , [27] , [28] .
Novel Cancer Treatments and p53 Functional Rescue
A long-held medical goal for anticancer therapy is achieving functional rescue of p53 cancer mutants by stabilizing the wild-type conformation, thereby activating apoptosis in cancerous cells and shrinking or killing the tumor. Several promising drug-like small molecules have been identified [29] , [30] , but their mechanisms of action and their spectra of activity are not known. This has led to intense scientific interest in the basic mechanisms of p53 functional rescue.
p53 Cancer Rescue Mutants
We established the existence of global functional rescue mechanisms for p53 cancer mutants [31] through studies of intragenic second-site suppressor mutations that restore native p53 function ("cancer rescue," "cancer suppressor," among other names). Surprisingly, a second-site p53 suppressor mutation can cooccur with a p53 cancer mutation such that functional effects cancel and the double mutant protein has normal p53 function.
A search for such suppressor mutations resulted in identification of a "global suppressor motif" involving core domain amino acids 235, 239, and 240 [32] . Specific amino acid changes of one or more of these restored p53 function to 16 of 30 of the most common p53 cancer mutants tested.
Terminology
In this paper, the terms active and inactive are used to describe mutant functionality. In other literature, an active mutant may be referred to as a "functional," "positive," or "rescued" mutant and an inactive mutant may be referred to as a "nonfunctional," "negative," or "cancer" mutant.
Computational Approaches to p53
The p53 mutant classification problem is to predict whether a given set of amino acid changes to the p53 core domain results in an active p53 protein or not. It is a difficult problem because the p53 protein is marginally stable at physiological temperature (37 C) . p53 cancer mutants can be destabilized by only a few kcal/mole [33] . Some p53 mutants are inactive at human physiological temperature (37 C), but regain activity at 30 C. It is a substantial challenge to predict mutant functional activity from sequence when it depends crucially upon such subtle nuances.
The first, and previously the only, systematic integrated computational analysis of p53 mutation data and structural effects was made by Martin et al. [34] . They correlated mutations in the IARC database [18] with structural and evolutionary features, but did not make predictions or consider mutant phenotypic function. In 34 percent of distinct cancer mutations, their analysis was able to find identifiable underlying structural changes that might be expected to affect protein folding or protein-DNA contacts, based on secondary structure, hydrogen bonding, backbone torsion angles, and solvent accessibility. Possibly explainable changes rose to 56 percent by including substitutions of amino acids that are 100 percent conserved across many species.
While their results are impressive, they highlight the difficult case of p53. Two-thirds of all distinct p53 cancer mutants lack even a single putative explanation in terms of identifiable underlying structural changes and nearly half have no putative explanation whatsoever.
A THEORY OF COMPUTATION ASSISTING EXPERIMENTALISTS TO PURSUE FUNCTION
A functional census of p53 cancer and suppressor mutations means a catalog of the functional effect of each mutation. The census assigns active or inactive labels to every mutant, by experimental determination or computational prediction. Initially, experimental work would focus on selective screens in relevant regions of the p53 core domain, where most mutations that inactivate p53 occur. Hits from the screens would provide an initial training set for computational predictors of mutant p53 activity. The result of tested computational predictions would be a larger pool of known mutants with experimental activities. The larger training set would yield more accurate computational predictors, leading to a repeating cycle of improving predictions and experiments. Once the computational predictor was sufficiently accurate, it would be used to guide experimental work by identifying interesting regions in the p53 sequence.
Functional Census of Mutation Sequence Space
This section defines procedures for 1. iterated predictions, 2. informative mutant selection, 3. cross-validation, and 4. periodic methodology updates.
Iterated Predictions
Let set Ki be the mutants known to be active or inactive at step i. Predict Ki with cross-validation using Ki as a training set. Select a set Xi of unknown mutants as described below in Section 2.1.2. Predict Xi blindly using Ki as a training set, and record the predictions. Determine functions for Xi experimentally and score the recorded predictions. Predict Ki, Xi, and Ki + Xi with cross-validation using Ki + Xi as a training set. Finally, let K{i + 1} equal Ki + Xi and advance to step i + 1. 
Informative Mutant Selection
Active learning is a technique for selecting the most informative unlabeled examples and was previously used successfully for drug discovery and cancer classification [35] , [36] , [37] . Here, the most informative mutant is determined by estimating its impact on classifier accuracy. First, suppose the unknown mutant is active, rebuild the classifier, and determine the new cross-validated accuracy on the training set. Then, suppose the mutant is inactive and repeat. The maximum increase in the cross-validated correlation coefficient (CC), for an unknown mutant (m), across both assumed classes is here called "curiosity" (1), (2 
The CC c;t for a given classifier (c) in the set of all component classifiers with training set (t) is calculated using the true positive (tp c;t ), false positive (fp c;t ), false negative (fn c;t ), and true negative (tn c;t ) receiver operator characteristic (ROC) statistics.
Overlap Exclusion Cross-Validation (OECV)
The usual cross-validation strategies may not be sufficiently stringent for mutation sequence spaces because the training set may contain mutants that differ in only trivial ways (irrelevant mutations) from mutants in the test set. In OECV, mutants are removed from the training set if they share more than one mutation with the mutant being predicted. Thus, no cancer/rescue pair ever occurs in both training and test sets. Even so, cross-validation can be a misleading estimator. A major strength of this paper and methodology is that all predictions are made blindly and are verified experimentally.
Periodically Update Methodology
During the course of the iterated mutant predictions, new information will become available about mutant behavior. This will lead to better theories to describe behavior and better classifiers to predict function. New information about mutant behavior is used periodically to update the classifier and framework (see Fig. 1 ).
Molecular Models and Statistical Learning
If molecular models and dynamics (MD) simulations could predict protein function correctly from one or a few amino acid changes, then computation would face an easy task. However, atomic models are not strictly accurate in atomiclevel detail due to structure prediction limitations with current tools. Current computer simulations cannot accurately predict the functional effects nor definitively predict the protein structure resulting from even one single key amino acid change. This is especially so for marginally stable proteins like p53. Our hypothesis is that: 1) Atomic models and MD simulations encode useful information, in the form of weak trends and tendencies that are partially correlated with molecular function, even when the molecular models themselves fail to achieve consistent, reliable, detailed atomic-level accuracy, and 2) statistical machine learning methods can extract that information in a useful way.
This Paper
The goals of this paper are: 1) to demonstrate machine learning and statistical predictions in synergy with molecular modeling (see Section 2.2) and 2) to perform a doubleblind test of the functional census methodology on p53 cancer rescue mutants (see Section 2.1).
To accomplish the first goal, we constructed molecular models of all mutants considered in this paper. We extracted predictive features as described in Section 3.4 and used the features to make the predictions described in the second goal. As a control, we constructed and optimized two purely string-based classifiers. They were used to make the same test predictions, based on the same training mutants, as for the molecular model-based predictions.
To accomplish the second goal, we began with a training set of 123 known p53 putative cancer rescue mutants experimentally determined to contain 52 active and 71 inactive mutants. These constituted K1, the initial known set. The test set consisted of 71 novel p53 mutants, selected and assayed by the Brachmann laboratory. These constituted X1 to X24 and were predicted by 24 iterations of Section 2.1.1 in groups of three mutants (the last group had two mutants). The experimentalists first released mutant identities, but sequestered all other information, including summary statistics. After each double-blind computational prediction was made, the corresponding experimental result was released.
Biological Advance
This paper will demonstrate a general methodology for the computer-aided functional census of protein mutation sequence spaces, together with its instantiation on a central cancer protein. Other groups can use the methodology to create a functional census for other proteins. For example, Karchin et al. [38] provide a practical system that automates the model-building described below. Thus, the techniques in this paper can be implemented on a large scale using tools available now. After a functional census has been achieved for several dozen cancer proteins, we will know a great deal more about cancer systems biology than we know now.
Computational Advance
This paper will demonstrate that machine learning and statistical methods extend the utility of modeling techniques, while atomic modeling methods improve the power and predictive accuracy of machine learning. This will advance molecular computation by extending both molecular modeling and machine learning/statistical methods into useful but poorly understood applications to molecular function.
METHODS
A multidimensional view of p53 mutant data is sketched schematically in Fig. 2 .
A Yeast p53 Functional Assay
The basic yeast p53 functional assay expresses human wildtype p53 from a CEN plasmid (maintained at one copy per cell) under the control of the constitutive yeast ADH1 promoter. Wild-type p53 binds to an artificial consensus p53 DNA binding site and transactivates the URA3 reporter gene, thus allowing yeast cells to grow on plates lacking uracil (Ura þ phenotype). The phenotype (active, inactive) is scored after two to three days at 37 C [31] . Intragenic suppressor mutations were initially screened for by PCR mutagenesis, followed by gap repair in yeast [32] . Once codons 239 and 240 were identified as suppressor codons, a saturation mutagenesis was performed for these two codons using oligonucleotides. A background mutagenesis was included for the remaining codons of the oligonucleotides (225 to 241). Annealed oligonucleotides were cloned into yeast expression plasmids for common p53 cancer mutants. The resultant libraries were transformed into the yeast reporter strain and Ura þ colonies were analyzed [32] . The results of these studies served as the basis for the training set.
The libraries for the p53 cancer mutants R158L, V173L, Y205C, Y220C, G245S, and R273H were used to generate a new test set for computational analysis. Yeast transformants were generated for each p53 cancer mutant and replicaplated to plates lacking uracil to determine the Uraphenotype. Ura À and Ura þ colonies were selected for each p53 cancer mutant, single-colony purified and retested for phenotype. The plasmids were rescued from yeast, sequenced, and transformed again into the yeast reporter strain for phenotype confirmation. This resulted in the isolation of 49 Ura À and 22 Ura þ p53 mutants that were unique (see Table 4 ). Thirty-nine Ura þ p53 mutants were excluded because they had been previously reported.
All plasmids for Y205C contained the spurious mutation D207V introduced during the library construction. For a previous study [32] , we separated Y205C from D207V and found that this did not change the observed rescue effects of suppressor mutations, such as N235K or N239Y. For the purpose of the current study, we therefore considered D207V to be a neutral amino acid substitution unlikely to impact rescue effects of the 235-239-240 rescue region.
Training and Test Data
Functional assays by the Brachmann laboratory characterized sets of p53 mutants for suppressor (rescue) properties. Because 1) all data was generated by one laboratory using the same assay and 2) results were reconfirmed by replicate testing, the data set is considered to be reliable and internally consistent. These data were described in Section 2.3.
Molecular Models
Machine learning and statistical techniques made the predictions using features derived from homology-based atomic models and molecular dynamics simulations.
Molecular modeling and Dynamics
All simulations were performed in the AMBER package [39] using the wild-type p53 core domain crystal structure [20] as a template. 3 All hydrogen atoms were added by the AMBER Leap module. The ff99 force field with a recent revision of the main chain torsion terms [39] was used. The Zn-binding interface in p53 was calibrated in a previous study (Lu and Luo, unpublished data). The generalized Born model [40] was used for solvation. The protein dielectric constant was set to 1.0. The water dielectric constant was set to 80.0. All nonbonded interactions were cut off at 12 Angstroms. The nonbonded list was updated every 20 steps. All bonds involving hydrogen atoms were constrained by the SHAKE algorithm [41] . Initial homology models of p53 mutants were constructed in the AMBER Leap module. Side chain rotamers of the mutated residue and closest neighboring residues were optimized by SCWRL 4 [42] to avoid clash. The models were then subjected to 1,000-step steepest descent minimization [43] in vacuum.
Unfolding simulations for p53 mutants were performed with linearly increasing temperature from 40 K to 1,000 K over 100 picoseconds. The radius of gyration in an unfolding trajectory was monitored to correlate with thermodynamic stability. Three molecular dynamics runs were performed to reduce uncertainty in the trajectories.
Features
Computational analyses used molecular model-based representations to create the component classifiers: (1D) genomic sequence, (2D) surface property maps, (3D) protein structure distance maps, and (4D) unfolding trajectories over time. Feature selection was done inside the cross-validation loop. As a control, two string-based classifiers also were constructed.
Sequence (1D)
Information about the location of the mutation and the residue change was used to construct the set of 1D structure features. Secondary structure information of the mutation (alpha helix, beta sandwich, etc.) was recorded with its general location in the p53 core domain (S1, S2, H1, H2). The residue property change was recorded: polarity, amino acid substitution, size, charge, aromaticity, hydrophobicity, and if in a DNA-binding region. Stability predictions from MUpro 5 [44] were also included, resulting in 247 features per mutant. 
Surface Property Maps (2D)
In its role as "guardian of the genome," p53 interacts with many molecules. The 2D surface maps the p53 surface that is available for molecular interactions and drug binding (see Fig. 3 ). The 2D surface property maps were annotated with surface properties, such as electrostatics or h-bond donor/ acceptor status provided by the electrostatic add-ons to AMBER 6 by Luo et al. [45] . The molecular surface was mapped to a sphere, steric and depth information was recorded, and the sphere was mapped to a plane.
The resulting surface map was subtracted from the wildtype map and a raw set of 4,883 steric surface map features and 4,895 electrostatic surface map features was extracted. A cross-validated mutual information algorithm selecting the 3,000 most relevant features (selected inside the crossvalidation loop) resulted in the best classifier.
Protein Structure Distance Maps (3D)
A structural mutation perturbs the molecular structure. The 3D distance map is an N Â N matrix giving the Cartesian distance between N residue alpha carbons. It reflects structural shifts induced by the mutation. The wild-type distance map is subtracted, leaving a difference map.
The p53 core domain has 197 residues, resulting in a 197 Â 197 matrix that may be collapsed to a distance vector giving the magnitudes of the distance changes (Fig. 4) . The resulting 197 length vector map had three features for each residue, the directional i, j, and k vectors. This resulted in 591 features per mutant.
Heating Simulation (4D)
The thermodynamic stability of a p53 mutant is an important determinant of cancer. The unfolding of a molecular model in a simulated heat bath is related to thermodynamic stability. The 4D data tracks the 3D structure of the molecule over time. For each ps time step, the radius of gyration averaged across three runs produced a vector with 99 features per mutant (see Fig. 5 ).
String-Based Control
A Support Vector Machine (SVM) was used for the stringbased classifiers because SVMs have been found to perform well on diverse biological data [47] . Two string-based classifier methods were selected. One, hereafter called string-match-based, used just k-mer match scores between sequences [47] and was optimized extensively and used in the composite classifier as an alternative 1D classifier. The other, hereafter called string-mismatch-based, used slightly different k-mer match scores with a mismatch tolerance parameter [48] . Both were tested with k from 2-5 and the mismatch tolerance m was tested from 0-1 to see which produced the highest cross-validated accuracy on the known data set. Ultimately, a kernel with k = 4 was selected for the string-match-based method and k = 5 with m = 0 was selected for the string-mismatch-based method.
Machine Learning
The WEKA machine learning software 6 Support Vector Machine algorithm [49] , [50] was used for 1-4D component classifiers. The composite classifier was constructed using an in-house implementation of the Naive Bayes algorithm [51] . In this implementation, statistics for each of the 1-4D component classifiers and all combinations thereof are used to determine the probability of each classifier correctly predicting a mutant. Specifically, let A be the event that mutant m is active, c½i be the ith component classifier trained on set t, C i ¼ c½iðmÞ be the prediction of c½i on m, and D i ¼ ðC 1 &C 2 . . . &C i Þ with D 0 ¼ ðÞ. Then, P ðAjD N Þ, the Bayesian probability that m is active given the predictions of the N component classifiers, is estimated as follows (3), (4), (5), (6): 
P ðC i jD iÀ1 Þ estimates the probability that a given component classifier makes an active or inactive prediction given all previous component classifiers. Ultimately, a mutant with P ðAjD N Þ greater than 0.5 was predicted to be active.
RESULTS
This section gives results from 1) the preparatory analysis, 2) the double-blind trials, and 3) the postmortem analysis. Table 1 summarizes the composite classifier on K1, the initial training set of 123 mutants. Table 2 shows each component classifier in cross-validated predictions, also on K1. Table 3 quantifies the correlation between predictions produced by the component classifiers. Table 4 presents the raw results achieved during the 24 iterations from Section 2.1. Fig. 6 shows accuracies derived from Table 4 . Accuracy is shown for both the predictions made in each iteration (predicting one group of three mutants) and for a moving window of 5-iteration moving average. As expected, prediction accuracy begins low (47 percent for the initial 15-point moving average) and climbs throughout the course of the experiment as the most informative mutants are identified and added to the training set (86 percent for the final 14-point moving average). Table 5 summarizes the predictive accuracy of the classifier on the double-blind test set. Fig. 7 shows an ROC curve and Table 6 shows a 2 Â 2 confusion matrix, for the predictions shown in Table 4 . Fig. 8 shows the curiosity outlined in Section 2.1.2. As expected, the mutants selected initially were more informative than those deferred until later in the process. Table 7 shows the cross-validated accuracy of the final mutant set (K25) predicting the behavior of different mutant subsets.
Preparatory Analysis

Double-Blind Trials
Postmortem Analysis
String-Based Control
We repeated the predictions using the same training and test sets in the same order as shown in Table 4 and Fig. 6 using two string-based controls (Section 3.4.5) as a direct comparison to the model-based classifiers (Sections 3.4.1-3.4.4) . Fig. 9 shows the composite prediction accuracy versus string-match-based and string-mismatch-based prediction accuracy. While the predictive accuracy of the string-match based k-mer predictor did increase over time, it was substantially lower than for model-based features. The string-mismatch-based classifier accuracy demonstrated no clear pattern. 
TABLE 2 Cross-Validated Accuracy of the Component Classifiers
Accuracies calculated using data set K1.
TABLE 3 Component Classifier Correlations
Correlation between the component classifiers (1D-4D) , the stringmatch based control and the composite classifier (C) created using cross-validated K1.
Random Control
A baseline for active learning is established by control trials wherein mutants are selected randomly. Fig. 10 shows the prediction progression using active learning (Section 2.1.2) versus the prediction progression using randomly selected mutants. Their accuracy increased slightly as more training data was added, but much less than the curiosity-based active learning.
CLASSIFIER METHODOLOGY IMPROVEMENTS
As discussed in Section 2.1.4, the computational models and biological experiments synergistically evolve while exploring the mutant space.
Motivation to Improve 2D Component Classifier
As demonstrated in Section 4.2, the composite classifier accuracy improved considerably while performing the iterated predictions. When analyzed in terms of the crossvalidated component classifier accuracy, two trends became apparent (see Fig. 11 ). The 1D classifier fell slightly in crossvalidated accuracy from approximately 75.8 percent to 69.1 percent, while the 2D classifier rose in cross-validated accuracy from 64.2 percent to 72.2 percent.
Surface Evolution by Functional Region
DNA and almost all small molecules bind to p53 around a promiscuous binding domain [52] on the surface of amino acids 94-160 and 264-315. The 2D surface was modified so that regions not in the promiscuous binding region were sampled at a lower resolution: Each amino acid was reduced to one surface position feature and one surface electrostatic feature. 
TABLE 5 Double-Blind Composite Classifier Accuracies
K1 and X1-X24 are the initial sets of known and unknown mutants (respectively). K1, X1-X24 (Pre) is a double-blind prediction using K1 to predict X1-X24. Ky-Kz*, Xy-Xz* are iterated predictions using sets Ky-Kz to predict iterations Xy-Xz (respectively).
TABLE 4 Predictions Grouped by Cancer Mutant Yeast
Assay is the activity observed at 37 C in Dr. Brachmann's laboratory. Prediction is made by the composite classifier outlined in this paper. Iteration is the iteration in which that mutant was predicted.
Regions within the promiscuous binding domain were sampled at the resolution described in Section 3.4.2. This resulted in 4,826 features rather than the 9,778 used during the iterated predictions (see Section 3.4.2). Several different feature set sizes were tested using the Weka Mutual Information algorithm [53] and 400 features yielded the consistently highest cross-validated accuracy across several training sets. The regions selected by the Mutual Information 
TABLE 7 Cross-Validated Composite Classifier Accuracies
Variables as defined in Table 5 . K25, X1-X24 (Post) is the crossvalidated accuracy predicting X1-X24 using K25 where K25 = (K1 + X1-X24). All trials were cross-validated using OECV (Section 2.1.3). algorithm on K25 can be represented visually as shown in Fig. 12 [54] . Most of the relevant residues cluster around the DNA binding region or around residue Y103. Table 8 shows the cross-validated accuracy for the 2D and composite classifiers using both the old and new 2D feature selection techniques.
New 2D Results
Improved Composite Classifier
As per Table 8 , a significant improvement in the 2D component classifier resulted in a small improvement in the overall composite classifier. To correct this, the composite classifier outlined in Section 3.5 was modified to weight more heavily component classifiers that did particularly well. For each component classifier, the score of correctly predicting an active (QðAjD i Þ) or inactive (QðIjD i Þ) mutant is shown in (7) and (8) 
The final prediction was calculated using (9):
where and are normalization constants over all component classifiers predicting active and inactive respectively. A mutant is considered active if Q > 0 (9).
DISCUSSION
This paper demonstrated a coordinated computational and experimental attack on the functional genomics of p53 cancer and suppressor mutants. To our knowledge, it is the first large-scale attempt to predict the phenotypic functional rescue of p53 cancer mutants. It showed:
1. A double-blind test of the functional census methodology on p53 cancer rescue mutants (see Section 2.1). Predictive accuracy rose over the course of the trial (see Fig. 6 ) and the more informative mutants were selected early (see Fig. 8 ). 2. Machine learning and statistical predictions working in synergy with molecular modeling (see Section 2.2). Model-based classifiers outperformed string-based classifiers in a control experiment (see Fig. 9 ). The composite classifier was relatively accurate (over 80 percent) when predicting cancer mutants V173L, Y205C, and R273H (see Table 4 ). However, it was inaccurate on cancer mutants R158L, Y220C, and G245S. We believe that more informative rescue mutants can be selected for these cancer mutants and additional trials are in progress. It is surprising that the 4D unfolding trajectories lagged in predictive power since they bear information about thermostability and p53 is a thermosensitive molecule. Nonetheless, 1,000 K is very high and 100 ps is very short. More biologically realistic unfolding regimes may help.
By analyzing the results of each round of predictions, new information about p53 and a better way to construct the classifier became available. This information was used to improve the classifier (see Section 5) and may also aid in understanding p53. 
Implications
The biological advance is a general method to catalog mutation sequence spaces across important proteins of medical interest, which may eventually extend to medical knowledge of entire pathways and networks. The computational advance is a method whereby robust statistical methods applied to noisy, biased, imperfect molecular models help experimentalists to pursue function in areas where, previously, the techniques were believed not to apply.
The broad goal is a comprehensive census of the functional rescue of p53 cancer mutants by second-site suppressor mutations. A functional census of suppressor mutations for p53 cancer mutants will significantly further our knowledge of p53 rescue mechanisms. Knowledge of all regions of the p53 core domain that improve stability when altered will provide guidance in choosing possible docking sites for small molecules.
The methodology generalizes to other mutational systems where mutants can be classified as active or inactive. Computational classifiers that predict mutant function will allow experimentalists to map structure/function relationships for proteins in other mutation-related diseases.
Conclusion
Central to the goal of cancer treatment by p53 functional rescue is better knowledge of p53 rescue mechanisms. Intragenic suppressor mutations pinpoint key regions of the p53 core domain that may be modified to increase stability of or restore binding domains in the p53 protein. This gives a validated point of control that restores native p53 function and identifies the cancer mutants that are amenable to functional rescue and, thus, the most likely drug targets. Our long-term goal is to exploit these findings for the design of drug compounds that can restore p53 function and preliminary small molecule studies are underway with our collaborators. 
